Pharmaceutical Regulatory Consultation

What we do: PKCS provides strategic regulatory consultation for pharmaceutical, biotechnology, and medical device companies considering entry, expansion, or major lifecycle changes in Iraq, the UAE, Saudi Arabia, and the wider GCC. Where regulatory affairs is the execution of filings, regulatory consultation is the strategy: which markets, which pathways, which timelines, and what it will actually cost.

When do companies need regulatory consultation?

Most regulatory consultation engagements are triggered by one of three moments: a board-level decision to enter the MENA region and a need for a clear-eyed view of the regulatory landscape; a planned acquisition or in-licensing deal where the regulatory status of the target portfolio needs independent verification; or a major lifecycle event — a manufacturing site change, a generic competitor entry, or a regulatory variation that materially affects market access.

In each case the deliverable is the same shape: a written regulatory strategy that names the target authorities, describes the pathway and dossier requirements at each, gives realistic timelines and likely deficiencies, identifies the regulatory risks that could materially delay or block approval, and quantifies the resources required to execute.

What does a regulatory consultation engagement look like?

• Market entry strategy — Which countries to file in, in what order, with what supporting evidence. Includes assessment of the GCC central pathway versus national filings.
• Pathway selection — For each target country, the optimal regulatory pathway (e.g., SFDA verification for products approved in reference markets vs full dossier review).
• Gap analysis — Comparison of the existing global dossier against the target country requirements, with a specific list of additional studies, documents, or labelling that will be needed.
• Regulatory due diligence — Independent verification of the regulatory status of a target portfolio in M&A or in-licensing transactions.
• Authority engagement strategy — Pre-submission meeting preparation, scientific advice, and management of authority interactions.
• Regulatory intelligence — Ongoing monitoring of changes to MENA regulatory frameworks (e.g., UAE Federal Decree-Law 38/2024 implementation, SFDA guideline updates, GCC Health Council decisions).

Who is regulatory consultation for?

Typical engagements are with senior regulatory affairs leadership at multinational manufacturers, business development teams evaluating MENA acquisitions, generics manufacturers planning new market entries, biotech companies pre-launching innovator products, and medical device manufacturers navigating GHTF-class registrations.

Related services

• Regulatory Affairs — Execution of dossier preparation and submission.
• Iraq Drug Registration — Country-specific guide to Iraqi MOH/KIMADIA filings.
• Local Representative Services — Local agent / marketing authorization holder representation.

Frequently asked questions

How is regulatory consultation different from regulatory affairs?

Regulatory affairs is execution: building and submitting the dossier. Regulatory consultation is strategy: deciding which markets to enter, which pathways to use, and what it will take to win approval. Most engagements start with consultation and then transition into regulatory affairs execution.

Can PKCS support due diligence for MENA acquisitions?

Yes. PKCS regularly conducts regulatory due diligence on portfolios being acquired or in-licensed, providing an independent view of registration status, pending variations, lifecycle risks, and likely future cost of regulatory upkeep.

Do you provide pre-submission meeting support with regional authorities?

Yes. PKCS prepares clients for and accompanies them to scientific advice and pre-submission meetings with MOHAP/EDE, SFDA, and Iraqi MOH where the authority offers such interactions.